• Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders
  • $4 million registered direct offering priced at market under Nasdaq rules
  • Proceeds are expected to be sufficient to fund the Company to mid-first quarter 2027
     

SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of $3.28 per share to existing shareholders, including insiders, with total gross proceeds of $4 million. The offering is expected to close on September 17, 2026.

The offering is expected to provide Clene with sufficient cash to fund its operations through mid-first quarter 2027.